Cargando…

Identification of SARS-CoV-2 entry inhibitors among already approved drugs

To discover effective drugs for COVID-19 treatment amongst already clinically approved drugs, we developed a high throughput screening assay for SARS-CoV-2 virus entry inhibitors using SARS2-S pseudotyped virus. An approved drug library of 1800 small molecular drugs was screened for SARS2 entry inhi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Li, Pei, Rong-juan, Li, Heng, Ma, Xin-na, Zhou, Yu, Zhu, Feng-hua, He, Pei-lan, Tang, Wei, Zhang, Ye-cheng, Xiong, Jin, Xiao, Shu-qi, Tong, Xian-kun, Zhang, Bo, Zuo, Jian-ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594953/ https://www.ncbi.nlm.nih.gov/pubmed/33116249 http://dx.doi.org/10.1038/s41401-020-00556-6

Ejemplares similares

Already!
Publicado: (1892)

Quinolizidines as Novel SARS-CoV-2 Entry Inhibitors
por: Huang, Li, et al.
Publicado: (2022)

Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro
por: Zhang, Qi, et al.
Publicado: (2020)

Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro
por: Zhang, Qi, et al.
Publicado: (2020)

Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library
por: Wang, Peilin, et al.
Publicado: (2018)

100 Already?
por: Negrin, Robert S.
Publicado: (2021)

SARS-CoV-2 was already spreading in France in late December 2019
por: Deslandes, A., et al.
Publicado: (2020)

SARS-CoV-2 was already in circulation in Northern Cyprus in the prepandemic period
por: Baddal, Buket, et al.
Publicado: (2021)

AN ALREADY SICK HEART: A CASE OF FATAL SARS-COV-2 MYOCARDITIS
por: GAJJALA, SRAVANI, et al.
Publicado: (2021)

Screening and Identification of Lujo Virus Entry Inhibitors From an Food and Drug Administration-Approved Drugs Library
por: Cao, Junyuan, et al.
Publicado: (2021)

Several FDA-Approved Drugs Effectively Inhibit SARS-CoV-2 Infection in vitro
por: Xiong, Hua-Long, et al.
Publicado: (2021)

The Booster is five already!
Publicado: (1977)

Visit the LHC... already!
Publicado: (2002)

Unveiling some FDA-approved drugs as inhibitors of the store-operated Ca(2+) entry pathway
por: Rahman, Saifur, et al.
Publicado: (2017)

Identification of NUDT5 Inhibitors From Approved Drugs
por: Tong, Xin-Yu, et al.
Publicado: (2020)

Screening of an FDA-Approved Drug Library with a Two-Tier System Identifies an Entry Inhibitor of Severe Fever with Thrombocytopenia Syndrome Virus
por: Yuan, Shuofeng, et al.
Publicado: (2019)

Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2
por: Dittmar, Mark, et al.
Publicado: (2021)

Mining of Ebola virus entry inhibitors identifies approved drugs as two-pore channel pore blockers()
por: Penny, Christopher J., et al.
Publicado: (2019)

Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein
por: Chen, Yuliu, et al.
Publicado: (2022)

Overview of therapeutic drug research for COVID-19 in China
por: Li, Heng, et al.
Publicado: (2020)

Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein
por: Wang, Lin, et al.
Publicado: (2021)

Structure-based discovery of dual pathway inhibitors for SARS-CoV-2 entry
por: Wang, Haofeng, et al.
Publicado: (2023)

What we already know about rhubarb: a comprehensive review
por: Xiang, Hong, et al.
Publicado: (2020)

Clinical HDAC Inhibitors Are Effective Drugs to Prevent the Entry of SARS-CoV2
por: Liu, Ke, et al.
Publicado: (2020)

Cell entry mechanisms of SARS-CoV-2
por: Shang, Jian, et al.
Publicado: (2020)

Botanical inhibitors of SARS-CoV-2 viral entry: a phylogenetic perspective
por: Risener, Caitlin J., et al.
Publicado: (2023)

Peptide and peptide-based inhibitors of SARS-CoV-2 entry
por: Schütz, Desiree, et al.
Publicado: (2020)

Screening of Natural Products Inhibitors of SARS-CoV-2 Entry
por: González-Maldonado, Pamela, et al.
Publicado: (2022)

Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2
por: Tripathi, Praveen Kumar, et al.
Publicado: (2020)

A new screening system for entry inhibitors based on cell-to-cell transmitted syncytia formation mediated by self-propagating hybrid VEEV-SARS-CoV-2 replicon
por: Li, Na, et al.
Publicado: (2022)

Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor
por: Han, Dong P., et al.
Publicado: (2006)

Tamoxifen and clomiphene inhibit SARS-CoV-2 infection by suppressing viral entry
por: Zu, Shulong, et al.
Publicado: (2021)

T-Cell Immunoglobulin and Mucin Domain 1 (TIM-1) Is a Functional Entry Factor for Tick-Borne Encephalitis Virus
por: Zhang, Xiaowei, et al.
Publicado: (2022)

Anti-Entry Activity of Natural Flavonoids against SARS-CoV-2 by Targeting Spike RBD
por: Meng, Jie-Ru, et al.
Publicado: (2023)

JUST ARRIVED... and already an expert on CERN
Publicado: (2001)

Lidocaine transdermal patches reduced pain intensity in neuropathic cancer patients already receiving opioid treatment
por: Tsai, Jui-Hung, et al.
Publicado: (2023)

A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entry
por: Chen, Yanwen, et al.
Publicado: (2021)

The FDA-approved drug Auranofin has a dual inhibitory effect on SARS-CoV-2 entry and NF-κB signaling
por: Laplantine, Emmanuel, et al.
Publicado: (2022)

Identification of Diaryl-Quinoline Compounds as Entry Inhibitors of Ebola Virus
por: Cui, Qinghua, et al.
Publicado: (2018)

Ebola Entry Inhibitors Discovered from Maesa perlarius
por: Tsang, Nga Yi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6ot2kckv7p98r3424b4edo34na